Literature DB >> 10984012

Nitazoxanide: pharmacokinetics and metabolism in man.

J Broekhuysen1, A Stockis, R L Lins, J De Graeve, J F Rossignol.   

Abstract

OBJECTIVES: Nitazoxanide (N), a new broad-spectrum parasiticidal agent, is rapidly deacetylated to tizoxanide (T). The objective of the study was to determine if metabolites other than T are present in the plasma and excreted after single dose oral administration of radiocarbon-labelled N in healthy subjects.
METHODS: Six healthy volunteers received a single 500 mg oral dose of N labelled with 2.92 MBq radiocarbon. The radioactivity in blood, plasma, urine, feces and expired air was monitored at scheduled intervals for up to 10 days. Selected samples were assayed by HPLC for T and submitted to metabolite identification by mass spectrometry. In vitro experiments were also conducted (incubation with animal and human microsomes, deacetylation kinetics). Plasma and bile samples obtained in a patient treated with N for sporozoal infection were also assayed for T.
RESULTS: Elimination of radiocarbon occurred both in the urine (31.5% of the dose on average) and in the feces (66.2% on average). T and T-glucuronide contributed 15% of total urine radioactivity. N was found to deacetylate extremely rapidly to T in plasma (half-life of about 6 minutes at 37 degrees C) as well as in presence of liver microsomes. T was the only species obtained by incubation with human microsomes while rat microsomes yielded hydroxylated T in addition. The main species identified in human plasma, urine and bile was T-glucuronide, the identification of which was confirmed by comparison with an authentic sample. No species other than T was detected in feces, indicating intensive intestinal deconjugation, while radioactivity and absorbance detectors showed largely unresolved clusters.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10984012     DOI: 10.5414/cpp38387

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  39 in total

1.  Synthesis and antimicrobial evaluation of nitazoxanide-based analogues: identification of selective and broad spectrum activity.

Authors:  T Eric Ballard; Xia Wang; Igor Olekhnovich; Taylor Koerner; Craig Seymour; Joseph Salamoun; Michelle Warthan; Paul S Hoffman; Timothy L Macdonald
Journal:  ChemMedChem       Date:  2010-12-29       Impact factor: 3.466

Review 2.  Future novel therapeutic agents for Clostridium difficile infection.

Authors:  Hoonmo L Koo; Kevin W Garey; Herbert L Dupont
Journal:  Expert Opin Investig Drugs       Date:  2010-07       Impact factor: 6.206

3.  In vitro effects of thiazolides on Giardia lamblia WB clone C6 cultured axenically and in coculture with Caco2 cells.

Authors:  Joachim Müller; Géraldine Rühle; Norbert Müller; Jean-François Rossignol; Andrew Hemphill
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  Biological activity of modified and exchanged 2-amino-5-nitrothiazole amide analogues of nitazoxanide.

Authors:  T Eric Ballard; Xia Wang; Igor Olekhnovich; Taylor Koerner; Craig Seymour; Paul S Hoffman; Timothy L Macdonald
Journal:  Bioorg Med Chem Lett       Date:  2010-05-18       Impact factor: 2.823

5.  Inhibitory activities of epidermal growth factor receptor tyrosine kinase-targeted dihydroxyisoflavone and trihydroxydeoxybenzoin derivatives on Sarcocystis neurona, Neospora caninum, and Cryptosporidium parvum development.

Authors:  G Gargala; A Baishanbo; L Favennec; A François; J J Ballet; J-F Rossignol
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

6.  Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis in vitro and in whole blood culture.

Authors:  Elizabeth P Harausz; Keith A Chervenak; Caryn E Good; Michael R Jacobs; Robert S Wallis; Manuel Sanchez-Felix; W Henry Boom
Journal:  Tuberculosis (Edinb)       Date:  2016-03-22       Impact factor: 3.131

7.  In Vitro Susceptibility of Canine Influenza A (H3N8) Virus to Nitazoxanide and Tizoxanide.

Authors:  Laura V Ashton; Robert L Callan; Sangeeta Rao; Gabriele A Landolt
Journal:  Vet Med Int       Date:  2010-08-12

8.  Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin.

Authors:  Tess Petersen; Yu-Jin Lee; Anu Osinusi; Valerianna K Amorosa; Crystal Wang; Minhee Kang; Roy Matining; Xiao Zhang; Diana Dou; Triin Umbleja; Shyam Kottilil; Marion G Peters
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-14       Impact factor: 2.205

9.  Nitazoxanide in treatment of Helicobacter pylori: a clinical and in vitro study.

Authors:  Yvonne Guttner; Helen M Windsor; Charlie H Viiala; Leon Dusci; Barry J Marshall
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

Review 10.  Nitazoxanide: a review of its use in the treatment of gastrointestinal infections.

Authors:  Vanessa R Anderson; Monique P Curran
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.